Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105521 · ClinicalTrials.gov registry record · Phase 3
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
A Phase 3 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 3
- Development phase
- 398
- Enrollment target
NCT00105521 is a Phase 3 study that has completed, run by EMD Serono. The registered enrollment target is 398 participants.
The verdict
NCT00105521, a Phase 3 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 398 participants
- Enrollment target
Study Summary
The purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.
Interventions
- DRUG Placebo
- DRUG Sarizotan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 398 participants |
| Start Date | 2004-09-30 |
| Est. Completion | 2006-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00105521
The ClinicalTrials.gov registry entry for NCT00105521 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 398 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00105521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00105521 about?
NCT00105521 is a clinical study titled "Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia". The purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.
What is the current status of trial NCT00105521?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 398 participants. The study started on 2004-09-30. Estimated completion is 2006-03-31.
What interventions are being tested in trial NCT00105521?
The interventions under investigation include: Placebo (DRUG), Sarizotan (DRUG).
Who is sponsoring clinical trial NCT00105521?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.